Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit $304.52 Billion by 2029

How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular degeneration. As an illustration, the National Health Service (NHS England), a publicly funded healthcare organization located in the UK, reported in June 2024 that the quantity of individuals predicted as pre-diabetic by the NHS in England had risen to 3,615,330 by 2023, showing an 18% escalation from 3,065,825 in the preceding year. Even more striking is the almost 25% rise in cases among those aged below 40, rising from 173,166 in 2022 to 216,440 in 2023. Hence, the burgeoning diabetes demographic is propelling the growth of these market sectors. Macular Edema and Macular Degeneration Market Driver: Growth in Macular Edema And Macular Degeneration Market Spurred by Rising Incidences of Eye Disorders

Get Your Macular Edema and Macular Degeneration Market Report Here:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What growth opportunities are expected to drive the macular edema and macular degeneration market's CAGR through 2034?
The market for macular edema and macular degeneration has seen robust growth in the past few years. The market value is predicted to rise from $9.65 billion in 2024 to $10.43 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historical period include an aging population, high diabetes prevalence, awareness and early detection, global commitments towards eye health, advancements in pharmaceuticals, and support and advocacy for patients.

The market for macular edema and macular degeneration is predicted to record significant expansion in the coming years, estimated to reach $13.71 billion by 2029, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the forecasted period include personalized medicine strategies, increased awareness in rising markets, emphasis on combined treatments, collaboration with teleophthalmology services, and the worldwide aging population. Key future trends will involve progress in sustained-release drug delivery, the incorporation of gene therapies, the emergence of innovative imaging technologies, personalized care plans centered on biomarkers, remote monitoring via teleophthalmology, and advancements in AI-based diagnostics.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

What are the emerging trends shaping the future of the macular edema and macular degeneration market?
In order to maximize their profits in the macular edema and macular degeneration market, leading corporations are concentrating on the innovation and development of new products like Vabysmo (faricimab-svoa). This particular drug, used in the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), was approved by the Food and Drug Administration in January 2022. Genentech Inc., a renowned biotechnology company based in the United States, was responsible for this breakthrough. Vabysmo (faricimab-svoa) is a unique bispecific antibody that targets angiopoietin 2 (Ang-2) as well as vascular endothelial growth factor (VEGF), becoming the first of its kind for these conditions. The projected success of Faricimab in the treatment of nAMD and DME, symbolized by the approval from both FDA and EU, marks a substantial achievement for both Genentech and Roche.

Which growth-oriented segments of the macular edema and macular degeneration market are leading the industry's development?
The macular edema and macular degeneration market covered in this report is segmented -

1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

What regions are leading the charge in the macular edema and macular degeneration market?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the macular edema and macular degeneration market?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Is Covered In The Macular Edema and Macular Degeneration Global Market Report?

•Market Size Forecast: Examine the macular edema and macular degeneration market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the macular edema and macular degeneration market for a structured understanding.
•Key Players Overview: Analyze major players in the macular edema and macular degeneration market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the macular edema and macular degeneration market.
•Segment Contributions: Evaluate how different segments drive overall growth in the macular edema and macular degeneration market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the macular edema and macular degeneration market.
•Industry Challenges: Identify potential risks and obstacles affecting the macular edema and macular degeneration market.
•Competitive Landscape: Review strategic developments in the macular edema and macular degeneration market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.